Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
To examine immune-inflammatory and oxidative (I&O) biomarkers in major depression (MDD) and its related phenotypes, we recruited 114 well-phenotyped depressed patients and 50 healthy controls and measured serum levels of interleukin (IL)-1α, soluble IL-1 receptor antagonist (sIL-1RA), soluble IL-2 receptor (sIL-2R), soluble IL-6 receptor (sIL-6R), soluble tumor necrosis factor receptor 60 and 80 kDa (sTNF-R1/R2), and thiobarbituric acid reactive substances (TBARS). Obtained results indicate that MDD is characterized by increased sIL-1RA, sTNF-R1, and TBARS concentrations. Melancholic depression is associated with increased sIL-6R but lowered IL-1α levels. A current episode of depression is accompanied by significantly increased sIL-6R compared to the remitted state. Treatment-resistant depression (TRD) is accompanied by increased sIL-6R and TBARS but lowered sTNF-R2 levels compared to non-TRD patients. These immune markers are not significantly correlated with Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Scale (MADRS), number episodes, or age at onset. Our findings show that increased sIL-1RA, sTNF-R1, and TBARS levels may be trait markers of depression, while increased sIL-6R levels may be a state marker of melancholia and an acute phase of depression. MDD is accompanied by increased lipid peroxidation and simultaneous activation of immune pathways, and the compensatory anti-inflammatory reflex system (CIRS). TRD is characterized by highly increased oxidative stress and probably increased TNFα and IL-6 trans-signalling. Novel treatments for major depression should target oxidative stress pathways, while new treatments for TRD should primary target lipid peroxidation and also activated immune-inflammatory pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683 · cited 1×
“Meta-analysis studies showed increased sIL-1RA levels in major depression (Howren et al. 2009; Goldsmith et al. 2016).”
BackgroundPeripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies
Köhler, C. A., Freitas, T. H., Maes, M., de Andrade, N. Q., Liu, C. S., Fernandes, B. S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12698 · Cited by 1,443 · cited 1×
“…consolidated in meta-analysis studies indicating increased IL-6, TNFα, sIL-2R, IL-1β, sIL-1RA, and C-reactive protein (CRP) levels in major depression (Howren et al. 2009; Dowlati et al. 2010; Liu et al. 2012; Hiles et al. 2012; Valkanova et al. 2013; Haapakoski et al. 2015; Köhler et al. 2017).”
BackgroundSelf-citationMaes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Self-citationHaapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129 · cited 1×
“…consolidated in meta-analysis studies indicating increased IL-6, TNFα, sIL-2R, IL-1β, sIL-1RA, and C-reactive protein (CRP) levels in major depression (Howren et al. 2009; Dowlati et al. 2010; Liu et al. 2012; Hiles et al. 2012; Valkanova et al. 2013; Haapakoski et al. 2015; Köhler et al. 2017).”
BackgroundCRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.004 · Cited by 972 · cited 2×
“Activation of immune-inflammatory pathways in major depression has now been consolidated in meta-analysis studies indicating increased IL-6, TNFα, sIL-2R, IL-1β, sIL-1RA, and C-reactive protein (CRP) levels in major depression (Howren et al. 2009; Dowlati et al. 2010; Liu et al. 2012; Hiles et al. 2012; Valkanova et a…”
BackgroundLiu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · cited 3×
“Previously, it was shown that increased levels of IL-6 are associated with TRD (Maes et al. 1997) and that baseline IL-6 production was significantly lower in treatment responders; while IL-6 was significantly higher in nonresponders to antidepressants (Lanquillon et al. 2000).”
BackgroundMaes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Self-citationDepression and sickness behavior are Janus-faced responses to shared inflammatory pathways
Maes, M., Berk, M., Goehler, L., Song, C., Anderson, G., Gałecki, P., & Leonard, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-66 · Cited by 629
Self-citationMaes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00028-l · Cited by 622
Self-citationMaes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.014 · Cited by 544 · cited 6×
“those who were euthymic (Maes 2011), suggesting that increased levels of cytokines (including IL-6 and sIL-6R) are trait markers of major depression.”
BackgroundInfluentialSelf-citationShelton, R. C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D. A., & Mirnics, K. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.52 · Cited by 511
A Meta-analysis of oxidative stress markers in depression
Liu, T., Zhong, S., Liao, X., Chen, J., He, T., Lai, S., & Jia, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138904 · Cited by 485 · cited 2×
“…to DNA and mitochondrial functions, oxidative damage to membranes, including increased expression of neoantigens such as malondialdehyde (MDA) and oxidized low-density lipoprotein (LDL), and lowered antioxidant levels including zinc (review Maes et al. 2011; Liu et al. 2015; Styczeń et al. 2017).”
BackgroundResultDahl, J., Ormstad, H., Aass, H. C. D., Malt, U. F., Bendz, L. T., Sandvik, L., Brundin, L., & Andreassen, O. A. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.019 · Cited by 424
Maes, M., Lin, A.-H., Delmeire, L., Van Gastel, A., Kenis, G., De Jongh, R., & Bosmans, E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00131-0 · Cited by 387
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Maes, M., Scharpé, S., Meltzer, H. Y., Okayli, G., Bosmans, E., D'Hondt, P., Vanden Bossche, B., & Cosyns, P. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90003-5 · Cited by 302
Self-citationMaes, M., Lambrechts, J., Bosmans, E., Jacobs, J., Suy, E., Vandervorst, C., De Jonckheere, C., Minner, B., & Raus, J. (1992) · Psychological Medicine · doi:10.1017/s0033291700032712 · Cited by 275 · cited 5×
“…antagonist (sIL-1RA), increased IL-6 trans-signaling (that is increased IL-6 and sIL-6R levels), and increases in positive acute phase proteins, such as haptoglobin, and complement factors (Maes et al. 1991, 1992b, 1994, 1995a, b; Słuzewska et al. 1995; Frommberger et al. 1997; Mikova et al. 2001).”
BackgroundInfluentialSelf-citationHiles, S. A., Baker, A. L., de Malmanche, T., & Attia, J. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.001 · Cited by 274 · cited 2×
“Thus in vivo, antidepressant treatments, especially with selective serotonin reuptake inhibitors (SSRIs), reduce IL-1β, CRP, and (maybe) IL-6 levels (Maes et al. 1995a; Hannestad et al. 2011; Hiles et al. 2012).”
BackgroundMaes, M., Bosmans, E., Suy, E., Vandervorst, C., DeJonckheere, C., & Raus, J. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03163.x · Cited by 268 · cited 7×
“Previous research also showed increased mitogen-stimulated IL-1β production and lymphocyte IL-1β mRNA levels in major depression (Maes et al. 1991; Rizavi et al. 2016).”
BackgroundInfluentialSelf-citationCytokine Production and Serum Proteins in Depression
SEIDEL, A., AROLT, V., HUNSTIGER, M., RINK, L., BEHNISCH, A., & KIRCHNER, H. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03604.x · Cited by 244 · cited 1×
“…e.g., Human Leukocyte Antigen-antigen D Related (HLA-DR) and cluster of differentiation 25 (CD25), resistance of cytokine production by immune cells to dexamethasone administration, and increased stimulated production of interferon (IFN)γ (Maes et al. 1990, 1991, 1992a, 1994; Seidel et al. 1995).”
BackgroundSukoff Rizzo, S. J., Neal, S. J., Hughes, Z. A., Beyna, M., Rosenzweig-Lipson, S., Moss, S. J., & Brandon, N. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.120 · Cited by 241 · cited 1×
“In an animal model of depression, sustained increases in central nervous system IL-6 may play a pathophysiological role underlying treatment resistance to antidepressants (Sukoff Rizzo et al. 2012).”
BackgroundSong, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Self-citationTargeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes, M., Anderson, G., Kubera, M., & Berk, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.888417 · Cited by 140
Self-citationGałecki, P., Szemraj, J., Bieńkiewicz, M., Zboralski, K., & Gałecka, E. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1014 · Cited by 124
Maes, M., Ombelet, W., De Jongh, Kenis, G., & Bosmans, E. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00156-7 · Cited by 116
Self-citationIncreased plasma levels of soluble TNF receptor I in patients with bipolar disorder.
Barbosa, I. G., Huguet, R. B., Mendonça, V. A., Sousa, L. P., Neves, F. S., Bauer, M. E., & Teixeira, A. L. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0116-z · Cited by 108 · cited 1×
“Another study in patients with coronary heart disease and depression was unable to find that increased serum IL-6 levels predict a poor response to treatment with antidepressants (Bot et al. 2011).”
BackgroundDunjic-Kostic, B., Ivkovic, M., Radonjic, N. V., Petronijevic, N. D., Pantovic, M., Damjanovic, A., Poznanovic, S. T., Jovanovic, A., Nikolic, T., & Jasovic-Gasic, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.009 · Cited by 99
Increased soluble tumor necrosis factor‐α receptors in patients with major depressive disorder
Grassi‐Oliveira, R., Brietzke, E., Pezzi, J. C., Lopes, R. P., Teixeira, A. L., & Bauer, M. E. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01918.x · Cited by 92 · cited 2×
“Previously, it was shown that depression is accompanied by increased sTNF-R2 levels (Grassi-Oliveira et al. 2009), while sTNF-R2 levels are also elevated in late life depression (Diniz et al. 2010).”
BackgroundRole of cytokines in atypical depression
Yoon, H.-K., Kim, Y.-K., Lee, H.-J., Kwon, D.-Y., & Kim, L. (2012) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2011.611894 · Cited by 65 · cited 7×
“These results may suggest that there is a difference in cytokine signature between melancholic and atypical depression the former being associated with M1 and Th1 activation and the latter with a Th1 shift away from Th2 (Maes 2011; Yoon et al. 2012).”
BackgroundResultInfluentialIncreased Soluble TNF Receptor 2 in Antidepressant-Free Patients with Late-Life Depression
Diniz, B. S., Teixeira, A. L., Talib, L. L., Mendonça, V. A., Gattaz, W. F., & Forlenza, O. V. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.02.008 · Cited by 54
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Wang, J., Um, P., Dickerman, B. A., & Liu, J. (2018) · Nutrients · doi:10.3390/nu10050584 · Cited by 350
The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder
Maes, M., & Carvalho, A. F. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1016-x · Cited by 306
Self-citationPeripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Sowa-Kućma, M., Styczeń, K., Siwek, M., Misztak, P., Nowak, R. J., Dudek, D., Rybakowski, J. K., Nowak, G., & Maes, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.08.024 · Cited by 104
Self-citation
Metadata
- Authors
- Sowa-Kućma, M., Styczeń, K., Siwek, M., Misztak, P., Nowak, R. J., Dudek, D., Rybakowski, J. K., Nowak, G., & Maes, M.
- Venue
- Neurotoxicity Research
- Published
- 2017-11-04
- Volume
- 33
- Issue
- 2
- Pages
- 448-460
- ISSN
- 1029-8428 (ISSN-L)
- 1476-3524
- OpenAlex
- W2766569620
- Cited by
- 87
- References
- 34
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.